Scientific Fellow, Janssen Pharmaceutica Inc
As of February 2018, Don has been the Technical Lead for the Chimeric Antigen Receptor T- Cells therapeutic area at the new clinical and commercial production site being built in Raritan NJ. His role includes oversight of construction & facility design, supply chain design, technical transfer activities and interactions with partner Legend Biotech as we target a last line of defense for multiple myeloma.
Don started in the industry back in 1995 at Centocor Inc shortly after receiving his Bachelor of Science in Biology along with a minor in Chemistry from Messiah College. He worked for several years in R&D and Cell Culture Development on mammalian cell lines and monoclonal antibody development. He spent several years as a technical SME overseeing the scale up, manufacture, and regulatory audit support for REMICADE® the multi-billion dollar drug which was one of the first ventures for Johnson and Johnson into the biotech arena. He continued supporting Remicade as both a Manufacturing Manager and an Investigations Manager.
In 2012 he switched his focus from monoclonal antibodies over to the Cell Therapies where he spent the next nearly six years overseeing both the clinical production of a phase 2 allogeneic cell therapy as well as the development and scale up of a manufacturing process in preparation for phase 3 and commercial launch.